Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / FHIT

FHIT

Basics

Aliases:
This biomarker is also known as:
  • Fragile histidine triad protein,
  • AP3A hydrolase,
  • Dinucleosidetriphosphatase,
  • FRA3B,
  • tumor suppressor protein,
  • EC 3.6.1.29,
  • AP3Aase,
  • Diadenosine 5',5'''-P1,P3-triphosphate hydrolase,
  • dinucleosidetriphosphatase,
  • bis(5'-adenosyl)-triphosphatase,
  • diadenosine 5',5'''-P1,P3-triphosphate hydrolase,
  • fragile histidine triad gene,

View in BioMuta

Description…

FHIT, or fragile histidine triad, is a member of the histidine triad gene family. The FHIT protein is a diadenosine 5',5'''-P1,P3-triphosphate hydrolase involved in purine metabolism. Included in the FHIT gene is the common fragile site FRA3B on chromosome 3, where carcinogen-induced damage can lead to translocations and aberrant transcripts of this gene. Mutated transcripts from this gene have been found in about half of all esophageal, stomach, and colon carcinomas. There are several alternatively spliced transcript variants for this gene.

Attributes

QA State: Under Review
Type: Protein
Short Name:
HGNC Name: FHIT

Datasets

There are no datasets associated with this biomarker.

Organs

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Resources

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.